Orchid Pharma Limited (ORCHPHARMA.NS)
INR 793.65
(-0.92%)
INR 793.65
(-0.92%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.41 Billion INR | 7.4% |
| 2022 | 1.42 Billion INR | 67.22% |
| 2021 | 635.81 Million INR | -2.26% |
| 2020 | 658.73 Million INR | 5944.74% |
| 2019 | 544.65 Million INR | -58.49% |
| 2018 | 2.06 Billion INR | -101.89% |
| 2017 | 359.97 Million INR | -62.46% |
| 2016 | -559.55 Million INR | -49.57% |
| 2015 | 1.43 Billion INR | -10.26% |
| 2014 | 3.53 Billion INR | 161.53% |
| 2013 | 1.48 Billion INR | -23.95% |
| 2012 | 1.32 Billion INR | -74.33% |
| 2011 | 3.28 Billion INR | -1.72% |
| 2010 | 4.21 Billion INR | -51.35% |
| 2009 | 8.67 Billion INR | 237.85% |
| 2008 | 2.56 Billion INR | -37.6% |
| 2007 | 4.11 Billion INR | 48.5% |
| 2006 | 2.76 Billion INR | 16.03% |
| 2005 | 2.38 Billion INR | 51.71% |
| 2004 | 1.57 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 324.91 Million INR | -23.14% |
| 2023 FY | - INR | 7.4% |
| 2023 Q1 | 240.28 Million INR | -41.98% |
| 2023 Q2 | 316.69 Million INR | 31.8% |
| 2023 Q3 | 430.05 Million INR | 35.79% |
| 2023 Q4 | 289.18 Million INR | -32.76% |
| 2022 FY | - INR | 67.22% |
| 2022 Q4 | 414.16 Million INR | 83.34% |
| 2022 Q1 | 153.8 Million INR | -48.61% |
| 2022 Q2 | 236.62 Million INR | 53.85% |
| 2022 Q3 | 225.9 Million INR | -4.53% |
| 2021 Q4 | 299.31 Million INR | 82.1% |
| 2021 Q1 | 26.93 Million INR | -89.95% |
| 2021 FY | - INR | -2.26% |
| 2021 Q2 | 130.72 Million INR | 385.36% |
| 2021 Q3 | 164.37 Million INR | 25.74% |
| 2020 FY | - INR | 5944.74% |
| 2020 Q4 | 268.11 Million INR | 938.29% |
| 2020 Q3 | -31.98 Million INR | -116.96% |
| 2020 Q2 | 188.63 Million INR | -8.3% |
| 2020 Q1 | 205.7 Million INR | 395.25% |
| 2019 Q1 | -70.76 Million INR | 0.0% |
| 2019 FY | - INR | -58.49% |
| 2019 Q4 | -69.67 Million INR | -196.21% |
| 2019 Q2 | 57.13 Million INR | 180.73% |
| 2019 Q3 | 72.41 Million INR | 26.76% |
| 2018 Q2 | 165.96 Million INR | 0.0% |
| 2018 FY | - INR | -101.89% |
| 2017 Q2 | 284.84 Million INR | 0.0% |
| 2017 FY | - INR | -62.46% |
| 2016 FY | - INR | -49.57% |
| 2015 FY | - INR | -10.26% |
| 2015 Q1 | 594.29 Million INR | 0.0% |
| 2014 FY | - INR | 161.53% |
| 2013 Q2 | -60.05 Million INR | 0.0% |
| 2013 FY | - INR | -23.95% |
| 2012 Q4 | 203.71 Million INR | 0.0% |
| 2012 Q2 | 394.52 Million INR | 0.0% |
| 2012 FY | - INR | -74.33% |
| 2011 Q4 | 917.93 Million INR | 0.0% |
| 2011 FY | - INR | -1.72% |
| 2010 FY | - INR | -51.35% |
| 2009 FY | - INR | 237.85% |
| 2008 FY | - INR | -37.6% |
| 2007 FY | - INR | 48.5% |
| 2006 FY | - INR | 16.03% |
| 2005 FY | - INR | 51.71% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 681.59 Million INR | -108.214% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -10820.122% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 77.05% |
| FDC Limited | 3.38 Billion INR | 58.079% |
| Gufic Biosciences Limited | 1.48 Billion INR | 4.141% |
| Hikal Limited | 2.69 Billion INR | 47.286% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 79.317% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 45.554% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -393.756% |
| Medico Remedies Limited | 129.09 Million INR | -999.338% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 7.581% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -521.972% |
| RPG Life Sciences Limited | 1.28 Billion INR | -10.744% |
| Sequent Scientific Limited | 549.8 Million INR | -158.126% |
| Shilpa Medicare Limited | 2.58 Billion INR | 45.163% |
| Sigachi Industries Limited | 883.39 Million INR | -60.65% |
| Themis Medicare Limited | 562.6 Million INR | -152.251% |
| Unichem Laboratories Limited | 742.35 Million INR | -91.172% |
| Venus Remedies Limited | 711.8 Million INR | -99.379% |
| Wanbury Limited | 985.49 Million INR | -44.007% |
| ZIM Laboratories Limited | 462.09 Million INR | -207.117% |
| Lupin Limited | 36.96 Billion INR | 96.161% |
| Innova Captab Limited | 1.66 Billion INR | 14.933% |
| Ind-Swift Limited | 1.06 Billion INR | -33.248% |
| Bajaj HealthCare Limited | 406.23 Million INR | -249.347% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.703% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 150.292% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 39.784% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -711.21% |
| Morepen Laboratories Limited | 1.72 Billion INR | 17.774% |
| Laurus Labs Limited | 8 Billion INR | 82.274% |
| Aarti Drugs Limited | 3.24 Billion INR | 56.315% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 79.321% |
| Alembic Limited | 1.11 Billion INR | -27.128% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 85.243% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 87.489% |
| Vaishali Pharma Limited | 31.71 Million INR | -4375.352% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 63.698% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -338.749% |
| Jubilant Pharmova Limited | 8 Billion INR | 82.274% |
| Eris Lifesciences Limited | 6.98 Billion INR | 79.687% |
| Windlas Biotech Limited | 781.72 Million INR | -81.546% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.974% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -5.647% |
| Albert David Limited | 1.04 Billion INR | -35.752% |
| Hester Biosciences Limited | 539.47 Million INR | -163.069% |
| Sakar Healthcare Limited | 393.26 Million INR | -260.868% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 69.657% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 53.839% |
| Divi's Laboratories Limited | 25.43 Billion INR | 94.419% |
| Mankind Pharma Limited | 28.09 Billion INR | 94.949% |
| Neuland Laboratories Limited | 4.74 Billion INR | 70.111% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 84.797% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.476% |
| Wockhardt Limited | 1.08 Billion INR | -31.405% |
| Bal Pharma Limited | 345.59 Million INR | -310.652% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.392% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 4.047% |
| Alkem Laboratories Limited | 24.19 Billion INR | 94.134% |
| Valiant Laboratories Limited | 12.73 Million INR | -11040.427% |
| Ajanta Pharma Limited | 12.56 Billion INR | 88.706% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -1138.56% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -3042.21% |
| Granules India Limited | 8.6 Billion INR | 83.505% |
| Medicamen Biotech Limited | 245.66 Million INR | -477.7% |
| Ipca Laboratories Limited | 13.29 Billion INR | 89.329% |
| Brooks Laboratories Limited | 41.72 Million INR | -3301.023% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -229.83% |
| Piramal Enterprises Limited | -3.86 Billion INR | 136.756% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 95.946% |
| NATCO Pharma Limited | 18.79 Billion INR | 92.449% |
| Suven Life Sciences Limited | -992.78 Million INR | 242.95% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1815.497% |
| Strides Pharma Science Limited | 3.76 Billion INR | 62.303% |
| Indoco Remedies Limited | 2.64 Billion INR | 46.386% |
| Alpa Laboratories Limited | 229.96 Million INR | -517.139% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2280.668% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 138.033% |